OncLive SOSS

HER2 Alterations in Non-Small Cell Lung Cancer - Episode 3

Liquid vs Solid Tumor Biopsies in NSCLC

September 20, 2022

Solange Peters, MD, PhD, Timothy Craig Allen, MD, JD, FCAP, Ticiana A. Leal, MD, Mark A. Socinski, MD, Anil Vachani, MD, MS

Mark A. Socinski, MD, debates the merits of liquid versus tissue tumor biopsies in NSCLC biomarker testing.

Video Player is loading.

Current Time 0:00

Duration 5:35

Loaded: 0%

Stream Type LIVE

Remaining Time 5:35

EP. 1: Biomarker Testing in NSCLC: Clinical Scenario

EP. 2: Approaches to Biomarker Testing in NSCLC

EP. 3: Liquid vs Solid Tumor Biopsies in NSCLC

EP. 4: HER2 Alterations in NSCLC: Clinical Scenario

EP. 5: The Role of HER2 Alterations in NSCLC

EP. 6: Testing Patients with NSCLC for HER2 Mutations

EP. 7: Current Treatment Options in NSCLC

EP. 8: Clinical Scenario: A 72-Year-Old Man with HER2-Amplified NSCLC

EP. 9: HER2-Targeted Therapies in NSCLC

EP. 10: Major Adverse Events of Anti-HER2 Therapies

EP. 11: Unmet Needs in NSCLC Therapy

EP. 12: Challenges and Unmet Needs in HER2-Mutated or Amplified NSCLC

EP. 13: Novel HER2-Targeted Therapies for NSCLC

x